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SUMMARY
(1) With the aid of specific antisera against each of the coagulation factors II
(prothrombin), IX and X, it could be demonstratedthat three different proteins occur
in the plasma of the cow receiving phenprocoumon that are absent in normal plasma.
These proteins are called 'proteins induced by vitamin K absence' (PIVKA$.
(2)Eachof the three PIVKAs has antigenic determinants in common with only
one of the three factors mentioned. We therefore speak of PIVKA-II, PIVKA-IX
and PIVKA-X.
(3) In the absence of calcium ions the normal factors and the PIVKAs have the
r s&(no electrophoretic mobility. In the presence of calcium ions the electrophoretic
mobility of the normal factors decreases but that of the PIVKAs remains unaltered.
(4) Quantitative immunoprecipitation and one-dimensional Laurell electro-
phoresis indicate that the sum of the concentration of normal factors and PIVKA
in the plasma of cows receiving phenprocoumon is roughly equal to the concentration
of the normal factor in the untreated cow.
(5) PIVKA-II can be converted into thrombin by prothrombinase, although
much more slowly than normal prothrombin.
(6) PIVKAs differ from normal coagulation factors as to their adsorbability
onto A1(OH)3.
INTRODUCTION
The 4 coagulation factors II (prothrombin), VII, IX and X have many proper-
ties in common. Their adsorption characteristics and molecular weights are very
similar, therefore they are difficult to separate. Yet these factors can be separated and
antibodies can be prepared that do not recognize common antigenic determinantsl.
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The available data upon primary structure and enzymatic activity suggest that they
are strongly homologous proenzymes of serine esterases2-4. The activity of the 4
factors in the circulating plasma decreases in real vitamin K deficiency and in func-
tional vitamin K deficiency induced by administration of vitamin K antagonists
(coumarins or indandiones). From experiments on the kinetics of the blood coagula-
tion process in normal and in vitamin K-deficient patients Hemker et al. inferred
the existence of plasma proteins induced by vitamin K absence (PIVKA$ in the
human5.
PIVKA may be defined as a protein occurring in plasma under conditions of vi-
tamin K deficiency having antigenic determinants in common with one of the factors
II, VII, IX and X, but possessing no activity in a coagulation test. As there are 4
vitamin K-dependent coagulation factors, one can postulate the existence of 4 PIVKAs.
These proteins will be referred to as PIVKA-II, PIVKA-VII, PIVKA-IX and PIVKA-
X, respectively.
PIVKA-II seems to be a well-defined entity, as it has been shown to occur in
the plasma of humans and cows deficient in vitamin I( or to whom vitamin K antag-
onists are administered. The protein from human origin converts into thrombin
much more slowly than normal factor 116 but like normal prothrombin obtains a
thrombinlike activity when incubated with staphylocoagulaseT,s. PIVKA-II precipi-
tates antibodies against normal factor II. The protein shows the same electrophoretic
mobility as normal factor II, but the mobility in the presence of calcium lactate is
faster than that of normal prothrombin, and it is not adsorbed onto barium citrate
in contrast to normal factor IIe-12.
The observations that plasma of patients on anticoagulant treatment neutralize
antibodies against the coagulation factors IX13 and X1a and contain a competitive
inhibitor of factor X conversion15,16 are indicative of the existence of PIVKA-IX
and PIVKA-X in the human. In this article PMA-IX and PIVKA-X are demon-
strated to occur in the anticoagulated cow besides PIVKA-II. It is also shown that
these PIVKAs differ from the normal factors with respect to their adsorbability onto
aluminum hydroxide. A preliminary report on the demonstration of these proteins
appeared previouslylT.
MATERIALS AND METHODS
Normal bovine factors II, IX and X, used for the immunization of rabbits,
were purified according to the method of Reekersl8. Common inorganic chemicals,
reagent grade, were obtained from Merck, Darmstadt, G.F.R. Marcoumar was a
kind gift from Dr. R. M. Kunz (Hoffmann-La Roche, Basel, Switzerland). Agarose
was a product of Koch-Light Laboratories Ltd. Aluminium hydroxide, moist gel,
was purchased from British Drug Houses Ltd.
Preparation of rabbit anti-bovine factor II, IX qnd X antiserum
Antisera were prepared in rabbits by injection of purified preparations of the
bovine factors II, IX and X. Antisera were treated with barium sulphate (100 mg/ml)
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fbr 30 min at room temperature and heat inactivation was performed for 30 min at
57 "C. The adsorbed and heat inactivated antisera were centrifuged for I h at 105,000
x C @ 'C). Sodium mertiolate (0.01% final concentration) was added before storage
at --20'C.
Immuno chemic al met ho ds
Double immunodiffusion was performed according to Ouchterlonyle' The one-
and two-dimensional crossed immunoelectrophoresis was done according to Laurellz0.
Immunoprecipitation was performed after Kabat and Mayer2l; mixtures of a fixed
amount of antiserum (0.1 ml) plus a variable amount of antigens were incubated for
30 min at 37 "C and 72ln at 4"C. The immunoprecipitate was collected by centrifu-
gation for I h at 5000 x g followed by 4 washings with 0.15 M NaCl at 0'C. The
incubation mixtures contained l0 mM EDTA in order to prevent Ca2+-dependent
complement fixation to the immunoprecipitatezz. After dissolution into 0.2m1
0.2 M NaOH the protein content of the immunoprecipitate was determined according
to Lowry et q1,23,
Antiserum neutralization tests were carried out by incubation of 0.1 ml anti-
serum with the desired amount of plasma depending on the titer of antigen in plasma
samples.
Co agulation fact or as say s
Coagulation times speciflcally dependent upon the concentrations of factor II,
VII or X were obtained by mixing in a test tube in a water bath at 37 "C, 0.1 ml
human plasma congenitally deficient in either factor II, VII or X, 0.1 ml human brain
thromboplastin and 0.1mI sample. The coagulation reaction was started by adding
0.1 ml of CaClz (33 mM). The moment of coagulation was assessed with the aid of a
platinum hook. Coagulation times dependent upon the factor IX concentration were
measured as described by Veltkamp et al.za.
Coagulation factor concentrations are expressed as a percentage ofthe content
in normal bovine plasma. The concentrations were calculated from the coagulation
times in speciflc tests as described by Hemker et a1.25 and Veltkamp et al'24.
Normal bovine plasma was obtained from a healthy cow, weighing about 550 kg,
and 5 litres of blood were obtained by puncture of the jugular vein. The blood was
centrifuged for 10 min at 1000 x I at 4 "C. The supernatant plasma was centrifuged
for 30 min at 12,000 x g. The supernatant thrombocyte-poor plasma was stored in
I ml and 5 ml vials at - 20 "C.
Plasma under conditions of vitamin K absence was obtained from the same cow
after phenprocoumon had been administered in two loading doses of 550 and 300 mg
on two subsequent days and a daily administration of 250 mglday for a further 21
days. The pertinent coagulation factor concentrations were: factor II, 8%; factor VII,
I2/o; factor IX, 10 f; factor X, ll%. The other factors were in the normal range
S0 100 %. This or similar plasmas will be referred to as coumarin plasma. Essentially
the same results were obtained with coumarin plasmas from 5 other cows.
i
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Fig. 1. Double immunodiflusion pattern of the antibodies used. center well: normal bovine plasma;
wells 1 and 4: anti-factor lI antiserum;wells 2 and 5: anti-factor IX antiserum; wells 3 and 6: anti-
factor X antiserum. Nun-rbering starts at the top and is clockwise'
RESULTS
Preparations of monospecific antisera against bovine factor II, IX and X
The antisera developed against factor II, IX and X were monospecific' This is
illustrated in Fig. I and Table I. The figure shows the non-identity of both antigens
and antibodies. The table shows that the bovine coagulation factor activities II, IX and
X are specifically inhibited by each of the three antibodies'
Qualitative qnalysis
Double itffision immunoprecipitation experiments' Double diffusion experiments
for the detection of material precipitating with antibodies against factor IX ale shown
in Fig. 2. A substance can be demonstrated in normal plasma, coumarin plasma,
Al(OH)e-adsorbed coumarin plasma, A1(OH)g-adsorbed coumarin serum and
normal bovine serum that shows a reaction of complete identity with factor IX in
normal plasma. The same can be demonstrated for factor X (Fig' 3)' The results with
antibody against factor II (not illustrated) were completely comparable to those shown
in Fig. 2, as would be exPected.
Two-dimensional crossed electrophoresl-s. The first of two-dimensional crossed
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TABLE I
NEUTRALIZATION OF COAGULATION FACTOR ACTIVITY BY ANTISERA
The antisera were treated with BaSOa and kept at 56'C for 10 min which abolished all procoagulant
activity. Antiserum (0.1 ml) was incubated for t h at 37"C with 2.0m1 plasma diluted l:5 with
veronal acetate buffer, pH 7.35. Serum from non-immunized rabbits was used as a control. The coa-
gulation times were obtained in a mixture of 0.1 ml sample, 0.1 ml tissue thromboplastin, and 0.1 ml
human plasma congenitally deficient in the factors to be tested; for factor IX the method of Veltkamp2a
was used. The coagulation times are in seconds, means of 7 estimations.
Plasma Antiserum against
lactor
Coagulation time obtained in a specifially deficient system
Factor IX Factor X
deficient deficient
Factor II
deficient
Factor VII
deficient
Bovine
Bovine
Bovine
Bovine
Human
Human
Human
Human
Buffer
II
IX
X
control
II
IX
X
control
49.3
27.3
28.1
27.6
21.9
20.7
20.5
20.0
133.0
23.8
23.4
25.2
23.8
24.4
1 1  a
22.7
20.5
126.3
1 3 8
450
142
1 3 5
1 1 3
3 1 8
1 1 1
108
365
34.1
31.4
133.7
34.4
30.3
28.4
27.9
28.0
135.5
electrophoresis experiments was carried out in the absence of calcium ions, or with
the addition of calcium lactate (2.5 mM final concentration) to the sample, the buffer
and the gel. When no calcium lactate was present, single peaks were obtained with
both normal and coumarin plasma when run against either anti-factor IX or anti-
factor X antibody (not illustrated). In the presence of calcium lactate the normal plasma
still showed one peak, but the coumarin plasma showed a second peak (Figs. 4 and
5). From the plasma of a cow anticoagulated for 24 h two peaks of about equal height
were obtained; one with an electrophoretic mobility equal to that in normal plasma,
the other one faster. From the plasma of the same cow receiving phenprocoumon for
7 days, only the fast peak remained. It was also observed with factor II as has already
been reported by otherse,lo.
Quantitative analysis
Immunoprecipitation, Immunoprecipitation curves of coumarin plasma with
antibodies against factor II, factor IX, and factor X are shown in Figs. 6,7 and 8. It can
be seen that: (1) the amount of material precipitated is roughly equal in normal and in
coumarin plasma although the coumarin plasma only has aboutl0\ of the coagulation
factor activity of the normal plasma; and (2) the precipitation equivalence was not
the same in normal and coumarin plasma. The latter finding shows that it will be
impossible to obtain an exact quantitation of the PIVKAs by immunochemical means.
One-dimensional crossed electrophoresis. After homogenous distribution of
antiserum in l\ agarose, the amount of immunoreactive material present in plasma
was determined by one-dimensional electrophoresis, according to Laure1120. The sur-
Fig. 2. Double diffusion immunoprer:ipitation with antibody against factor lX' Nr"rmbet'ing starts
at the top and is counterclockwise. 1: normal plasma; 2: coumarin plasrna;- 3: 'Al(OH):r-adsorbed
"oulnu.i., 
plasma; 4: Al(oH):r-adsorbecl normal plasma; 5: Al(oH)r-adsorbed coumarin serum;
6: A1(oH):-absorbed normal Serum; center well: anti-bovine factor [X antiserum.
face under the immunoprecipitation peak or the peak length show a l inear lelation
with the quantity of uniig.n applied. Fig. 9 shows the result of an experinlent using
anti-factor IX in the gel. Although the coumarin plasma used contained only l0[
fesidual normal factor IX as determined by clotting factor assays, peak lengths were
obtained slightly higher than those observed with normal bovine plasma' Aluminum
hydroxide treatment of normal plasma or serum completely removed the antigen;
aluminum hydroxide-adsorbed coumarin plasma still contained material precipitating
with anti-factor IX. Identical results were obtained with anti-factor II and anti-factor
X (Table l l ) .
B io logicalact iv i tyofP|VKA-I \ .Whencoumar inplasmaest imatedtoconta ln
20/"normalfactor I l was incubated with an excess of prothrombinase (l 'c' factor v
and Xu and phospholipid; for details of the method see refs. 6 and 26'), eventually an
amount of thrombin is generated that is roughly equal to the amount obtained from
a dilution of normal piur-u containing 40\ faclor Il. Adsorption with AI(OH)B
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Fig. 3. Double diffusion immunoprecipitation with antibody against factor X. Numbering starts at
the top and is  counterc lockwise.  1:normal  p lasma; 2:  coumarin p lasma; 3:  Al(OH)s-adsorbed
coumarin plasma; 4: Al(OH)s-adsorbed normal plasma; 5: Al(OH):-adsorbed normal serum;
6: Al(OH)r-adsorbed coumarin serum; center well: anti-bovine factor X-antiserum.
caused normal plasma to lose all thrombin generating potency but roughly the half
of the original amount could still be obtained from coumarin plasma after this treat-
ment (Fig. 10).
DISCUSSION
A protein induced by vitamin K absence analogous to prothrombin (PIVKA-lI
as defined in the introduction) has been demonstrated by many investigatorss'6's'77'12'
27. Our present results confirm these findings. The following arguments can be brought
forward in support of the existence of PIVKA-IX and PIVKA-X besides PIVKA-ll.
(a) Antibodies specific for one of the coagulation factors IX or X precipitate
much more material from coumarin olasma than can be accounted for bv the amount
l-
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Fig. 4. Two-dimensional crossed electrophoresis of bovine plasmas in the presence of calcium
lactate (first dimension, horizontal) and anti-factor IX antiserum (second dimension, vertical). a:
normal  p lasma; b:p lasma af ter  24 h ant icoagulat ion;  c:  p lasma af ter  100h ant icoagulat ion.
of normal factor IX or X in this plasma. Specific precipitation is improbable as a
cause for this finding because the coagulation activity in the supernatantcan be found
only in the zone of antigen excess (unpublished observations).
(b) The materials precipitable with antibodies against factor IX found in normal
plasma, coumarin plasma, normal serum, coumarin serum and A1(OH)a-adsorbed
coumarin plasma show immunologically a reaction of complete identity. No precipita-
ble material is found when normal plasma is adsorbed with Al(OH)s under circum-
stanoes known to remove all coagulation factor activity. A comparable observation
is made with antibody against factor X.
(c) Quantitation of material reacting with the antibodies in a one-dimensional
crossed immunoelectrophoresis according to Laure1120 shows that more material
is present in coumarin plasma and a fortiori in A1(OH)3-adsorbed coumarin plasma
than can be accounted for by the activity level of the coagulation factors.
We conclude that PIVKA-IX and PIVKA-X exist besides PIVKA-II in the
plasma of the cow receiving anticoagulants of the coumarin type. The PIVKA-II
upon incubation with prothrombinase does produce thrombin, but at a much slower
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Fig. 5. Two-dimensional crossed electrophoresis of bovine plasmas in the presence of calcium
lactate (first dimension, horizontal) and anti-factor X antiserum (second dimension, vertical)' a:
normal plasma; b: plasma after 24 h anticoagulation; c: plasma after l00h anticoagulation.
fate than normal prothrombin. The reason for the occurlence of PIVKA-IX and
PIVKA-X in the plasma of the anticoagulated cow has not yet been established. Our
original hypothesiss to explain the occurrence of PIVKA has been that a block of
the action of vitamin K causes an inhibition in a postribosomal stage of the pro-
thrombin synthesis and that PIVKA is the intermediate piling up because of this
block. The existing evidence as to prothfombin and PIVKA-I supports this view2z-31.
PMA-IX and PIVKA-X may arise in an analogous way.
Recent advances in chemical analysis of the difference between factor II and
PIVKA-II suggest that the vitamin-K dependent mechanism serves to modify glu-
tamic acid groups into 1r-carboxyglutamic acid groups that strongly bind Caz+
(ref. 32). The higher electrophoretic mobility in the presence of calcium ions suggests
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Fig. 6. Quantitative lmmunop.fecipitation of fagtol II' n, normal plasma; l' coumarin 
plasma' The
indicated amount of plasma'was incubated with 0.1 ml of anti-factor II antiserum as described 
under
Methods. In the zone or untiuoav excess, no factor II activity could be demonstrated 
in the super-
nrtant; in the zone of antigen excess such activity was present'
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Fig. 7. Quantitative immunoprecipitation of factor IX. O, normal plasma; O, coumarin 
plasma'
The indicated amount of plasma was incubated with 0.1 ml of anti-factor IX antiserum as described
under Methods. In the ,o* J u"tiUody excess, no factor IX activity could be demonstrated 
in the
supernatant; in the zone of antigen excess such activity was present'
1.2 15 2n U
ptasma(mt )
Fig. g. Quantitative immunoprecipitation of factor X. x, normal plasma; l, coumarin 
plasma' The
indicated amount of plasma was incubated with 0.1ml of anti-factor IX antiserum as described
under Methods. In the zone of antibody excess, no factor X activity could be demonstrated in the
supernatant; in the zone of antigen excess such activity was present'
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TABLE II
QUANTIFICATION OF ANTIBODY PRECIPITABLE MATERIAL IN VARIOUS PLASMAS
The figures give the amounts assessed as a percentage of normal plasma. P, material demonstrable
by one-dimensional crossed electrophoresis; B, biological activity. Adsorbed means that the sample
is adsorbed by l% (wlv) of Al(OH)g, adsorbed normal plasma showed neither precipitation nor
biological activity. Means of 5 estimations.
Factor II Factor IX Factor X
Normal serum adsorbed
adsorbed
Coumarin plasma
adsorbed
Coumarin serum
adsorbed
73
0
74
33
30
22
60
0
1 1 1
100
80
48
1 5
0
20
0
0
0
0
1 1 0
91
64
65
66
0
10
0
10
0
80
0
8
0
l 1
0
;ltg
: r i
Fig. 9. One-dimensional crossed immunoelectrophoresis against anti-factor IX antibody. I and 2:
normal plasma; 3 and 4: coumarin plasma; 5 and 6: normal serum; 7: coumarin serum; 8 : ALCBP
(adsorption time 5 min); 9 : ALCBP (adsorption time 30 min); 10: Ai(OH)e-adsorbed normal plasma;
11: A1(OH)s-adsorbed normal serum. Where two wells contained the same material, the second
well contained this material in a 1:1 dilution.
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Fig. 10. Thrombin generation test. At zero time the prothrombin-converting mixture was addedo
u.ri tt. amount of thrombin that developed is given as a function of time. x-x' normal plasma
diluted 1:5; A-4, normal plasma diluied 1:2; a-.O, dicoumarol plasma containing20T4pro-
thrombin in the one-stage tesi; O-O, the same dicoumarol plasma adsorbed with AI(OH): (1 %
that PIVKA-IX and PIVKA-X, like PIVKA-II (ref. l2), lack the ability to bind
calcium ions. As binding to a phospholipid-water interface via calcium ion is an
essential feature in the function of the normal factors IX and X (ref. 33) the inability
to bind Ca}+ may well account for the absence of biological activity.
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